Voices From the Field

As oncologists and the healthcare industry advance their practices to propel care for children, it is crucial for the industry and population at large to tailor care for the unique needs of children to maximize recovery and truly help patients thrive.

The knowledge gained from biomarker testing can help develop cancer prevention, diagnosis, and treatment strategies that specifically target a person’s cancer subtype.

As gene editing technology continues to advance, it could fundamentally change the landscape of cancer treatment.

Within the past decade, there has been a surge in terms such as value-based care, patient-centered care, shared decision-making, and more at the macro level of health care delivery in the US.

Adam C. Berger, MD, FACS, highlights the challenges and advancements in diagnosing and treating sarcoma, a rare and diverse group of cancers originating from mesenchymal tissues.

The latest research on circulating tumor DNA and circulating tumor cells isolated through liquid biopsies is revolutionizing cancer care by enabling early detection, treatment monitoring, and personalized medicine strategies.

The debate on non-specific vs targeted therapies in oncology highlights the need for a balanced approach optimizing existing agents while developing biomarkers and precision medicine.

The national shortage of nurses and health care support staff has spilled over to the clinical research space.

A cyberattack on Change Healthcare disrupted patient scheduling, billing, and potentially exposed patient data. It caused financial strain on medical practices and took weeks to recover from.

Change Healthcare, owned by UnitedHealth Group, was targeted by cybercriminals, affecting 140 million Americans and costing $1 billion daily. Recovery efforts underscore the critical need for robust cybersecurity measures in healthcare.

Clinical trials play a pivotal role in developing effective therapies, yet their integration is challenged by issues such as insufficient reimbursement structures, misaligned incentives, physician burnout, and a complex regulatory environment.

Until recently, the CAR gene modification has been focused on T cells, thought for decades to be the main effector population for controlling cancer or for harnessing cancer immunotherapy.

The frontline standard-of-care regimen for patients with higher-risk MDS and some with lower-risk MDS remain hypomethylating agents, such as azacitidine, decitabine, and decitabine/cedazuridine.

Improving patient prognostication in mantle cell lymphoma informs treatment decisions and enhances our understanding of the disease's biology.

By expediting referral processes, enhancing information quality, and boosting patient satisfaction, these systems are reshaping healthcare experiences for both providers and patients.

If the title is correct, an article in the November 10 issue of the Journal of Clinical Oncology shows that many randomized trials in oncology are improperly designed and many drugs used in oncology have been approved based on the wrong end point.

According to John M. Burke, MD, it is hard to imagine that results presented at ESMO in the urothelial cancer space will not lead to the complete replacement of conventional chemotherapy as the standard first-line treatment.

The recent announcement of the 2023 Nobel Prize in Physiology or Medicine has turned attention again to RNA therapeutic vaccines and a better understanding of RNA biology.

Allogeneic transplant is, today, a curative therapy for a variety of blood cancers, including many cases of acute monocytic leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes.

The rapid progress in oncology, along with complex cases and rising costs, presents challenges in delivering high-quality cancer care.

Currently, 6 separate bills have come out of congressional committees to increase pharmacy benefit managers regulation, with more transparency being the common factor.

The classes of cellular immunotherapies and those blocking negative regulatory signals, known as immune checkpoint blockade, have revolutionized cancer treatment.

Liquid biopsy is offering a noninvasive, real-time, and personalized approach to tumor assessment, and is already revolutionizing the field of clinical oncology.

John M. Burke, MD, discusses how Bruton tyrosine kinase inhibitors have demonstrated unexpected promise in treating follicular lymphoma, challenging previous assumptions in the field of oncology.

An era of advanced molecular testing and personalized medicine has allowed for the de-escalation of breast cancer treatment for many patients. This is part 1 of a 2-part series on overtreatment of breast cancer.

Robert L. Ferris, MD, PhD, discussed the growing use of bispecific antibodies and how he expects to see more of these advances in the coming years.

John M. Burke, MD, turns to ChatGPT to uncover what artificial intelligence may do for hematologists/oncologists.

A number of novel immunotherapies, such as PD-1 inhibitors and targeted drug therapies with BRAF and MEK inhibitors, have become available for managing advanced melanoma.

Oncologists are seeing early onset colorectal cancer more frequently, according to Jalal S. Baig, MD, medical oncologist at City of Hope Chicago.